{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/KAPA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Kairos Pharma, LTD. (NYSE: KAPA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Kairos Pharma, LTD., listed on the NYSE under the ticker KAPA. The ISIN is not on the record. The LEI is not on the record. The security type is Corporate. The segment is not on the record. The sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 33 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 9.0 days, against a median of 6.0 days for the NYSE and 6.0 days for the sector. The latest filing is dated 2026-11-05, which is 3 days before the record date. The latest filing is of type corporate news. The NYSE median filing count is 64.0 and the sector median is 63.0. The NYSE median latency is 4.0 days and the sector median latency is 4.0 days. The filings by type are 4 AGM/EGM, 11 corporate news, 7 directors' dealings, 3 prospectus, 4 regulatory filings and 4 results.\n\n## Auditor\n\nThe auditor of record is Weinberg & Company P.A., located in Los Angeles, CA. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names 4 research houses on the issuer's investor-relations page: Maxim Group, HC Wainwright, EF Hutton and D. Boral Capital.\n\n## Open research\n\nThe record holds 3 openly published research notes. Maxim Group published a note dated 2025-09-01, a note dated 2025-06-03 and a note dated 2025-03-27.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's sealed years are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n11 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://data.sec.gov/submissions/CIK0001962011.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NYSE/KAPA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx (coverage)\n- https://kairospharma.com/wp-content/uploads/2025/09/Positive-Interim-Phase-2-Data-For-ENV-105-in-mCRPC-Builds-Co.pdf (open research)\n- https://kairospharma.com/wp-content/uploads/2025/06/Maxim-Research-Report.pdf (open research)\n- https://kairospharma.com/wp-content/uploads/2025/03/KAPA.Maxim_.032725.pdf (open research)\n- https://mcp.us-cm-kg.ai/record/NYSE/KAPA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm",
    "state": "sourced",
    "value": "Weinberg\n& Company P.A."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm",
    "state": "sourced",
    "value": "572"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm",
    "state": "sourced",
    "value": "Los Angeles, CA"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/KAPA",
  "coverage": {
   "count": 4,
   "houses": [
    {
     "analyst": "Jason McCarthy",
     "house": "Maxim Group",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Joe Pantginis",
     "house": "HC Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Jason Kolbert",
     "house": "EF Hutton",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Jason Kolbert",
     "house": "D. Boral Capital",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx",
     "result": "read: 4 of 8 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 4,
    "corporate_news": 11,
    "directors_dealings": 7,
    "prospectus": 3,
    "regulatory_filing": 4,
    "results": 4
   },
   "cadence_median_gap_days": 9,
   "filing_days": 27,
   "filings": 33,
   "latency_days": 3,
   "latest": [
    {
     "category": "8-K",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226050094/form8-k.htm",
     "title": "8-K — 8-K (items 8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-11-03",
     "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226049744/form8-k.htm",
     "title": "8-K — 8-K (items 1.01,8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-10-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/form8-k.htm",
     "title": "8-K — 8-K (items 8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-09-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226042569/form8-k.htm",
     "title": "8-K — 8-K (items 7.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-08-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/form8-k.htm",
     "title": "8-K — 8-K (items 3.03,5.03,7.01,9.01)",
     "type": "corporate_news"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/KAPA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "market": "US",
    "reason": "no LEI, so no GLEIF ISIN route; EDGAR carries no ISIN",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001962011.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001962011.json",
    "state": "sourced",
    "value": "Kairos Pharma, LTD."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001962011.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001962011.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "KAPA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:0250c1a06aa0e63bb79b3cd2dab82d9975c19d6c139cec94cdf99a7f1b9994aa",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [
    {
     "date": "2025-09-01",
     "kind": "issuer-sponsored",
     "publisher": "Maxim Group",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://kairospharma.com/wp-content/uploads/2025/09/Positive-Interim-Phase-2-Data-For-ENV-105-in-mCRPC-Builds-Co.pdf",
     "state": "sourced",
     "title": "Positive Interim Phase 2 Data For ENV-105 in mCRPC Builds Compelling Profile and Extended PFS Benefit"
    },
    {
     "date": "2025-06-03",
     "kind": "issuer-sponsored",
     "publisher": "Maxim Group",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://kairospharma.com/wp-content/uploads/2025/06/Maxim-Research-Report.pdf",
     "state": "sourced",
     "title": "Kairos Pharma, Ltd. for ENV-105 in metastatic castration-resistant prostate cancer"
    },
    {
     "date": "2025-03-27",
     "kind": "issuer-sponsored",
     "publisher": "Maxim Group",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://kairospharma.com/wp-content/uploads/2025/03/KAPA.Maxim_.032725.pdf",
     "state": "sourced",
     "title": "Targeting CD105 Could Extend SOC Prostate and Lung Cancer Treatments – Initiating Coverage with a Buy"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/KAPA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:0250c1a06aa0e63bb79b3cd2dab82d9975c19d6c139cec94cdf99a7f1b9994aa",
 "path": "/us/NYSE/KAPA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Kairos Pharma, LTD., listed on the NYSE under the ticker KAPA. The ISIN is not on the record. The LEI is not on the record. The security type is Corporate. The segment is not on the record. The sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 33 filings in the twelve months to 2026-11-08, across 27 filing days. The median gap between filing days is 9.0 days, against a median of 6.0 days for the NYSE and 6.0 days for the sector. The latest filing is dated 2026-11-05, which is 3 days before the record date. The latest filing is of type corporate news. The NYSE median filing count is 64.0 and the sector median is 63.0. The NYSE median latency is 4.0 days and the sector median latency is 4.0 days. The filings by type are 4 AGM/EGM, 11 corporate news, 7 directors' dealings, 3 prospectus, 4 regulatory filings and 4 results.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Weinberg & Company P.A., located in Los Angeles, CA. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names 4 research houses on the issuer's investor-relations page: Maxim Group, HC Wainwright, EF Hutton and D. Boral Capital.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 3 openly published research notes. Maxim Group published a note dated 2025-09-01, a note dated 2025-06-03 and a note dated 2025-03-27.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's sealed years are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "11 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001962011.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/KAPA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://investors.kairospharma.com/stock-info/analyst-coverage/default.aspx"
  },
  {
   "for": "open research",
   "source": "https://kairospharma.com/wp-content/uploads/2025/09/Positive-Interim-Phase-2-Data-For-ENV-105-in-mCRPC-Builds-Co.pdf"
  },
  {
   "for": "open research",
   "source": "https://kairospharma.com/wp-content/uploads/2025/06/Maxim-Research-Report.pdf"
  },
  {
   "for": "open research",
   "source": "https://kairospharma.com/wp-content/uploads/2025/03/KAPA.Maxim_.032725.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/KAPA"
  }
 ],
 "title": "Kairos Pharma, LTD. (KAPA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}